Latest News
Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients
PXL065 is a new chemical entity derived from pioglitazone, which has shown to retain NASH efficacy without triggering peroxisome proliferator-activated receptor (PPAR)-g-related side effects in preclinical…
Read this Press Release: Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven PatientsPoxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology,…
Read this Press Release: Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic…
Read this Press Release: Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.
View Pipeline
Targeting Mitochondrial Dysfunction
Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and will be marketed by our strategic partner, Sumitomo Dainippon Pharma, in 2021. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.
View Our Candidates
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
